Trials / Conditions / Dedifferentiated Liposarcoma

Dedifferentiated Liposarcoma

18 registered clinical trials studyying Dedifferentiated Liposarcoma — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Pa NCT06975293	STORM Therapeutics LTD	Phase 1 / Phase 2
Recruiting	A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma NCT06843967	Memorial Sloan Kettering Cancer Center	Phase 1 / Phase 2
Not Yet Recruiting	Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk T NCT06526897	ECOG-ACRIN Cancer Research Group	N/A
Recruiting	A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors NCT06789172	Epkin	Phase 1
Not Yet Recruiting	First-line Treatment of Advanced/unresectable DDLPS NCT06694324	Fudan University	Phase 2
Recruiting	A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) NCT06389799	Lund University Hospital	Phase 2
Completed	Real-world Study of Dedifferentiated Liposarcoma Patients in China NCT06115681	Boehringer Ingelheim	—
Active Not Recruiting	A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma NCT05886634	Memorial Sloan Kettering Cancer Center	Phase 2
Terminated	TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma NCT05496569	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 2
Terminated	Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma NCT04979442	Rain Oncology Inc	Phase 3
Completed	Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas NCT04242238	Memorial Sloan Kettering Cancer Center	Phase 1
Terminated	Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors NCT03604783	Sumitomo Pharma America, Inc.	Phase 1
Active Not Recruiting	Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable NCT03307616	M.D. Anderson Cancer Center	Phase 2
Unknown	Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Ex NCT03651375	Maria Sklodowska-Curie National Research Institute of Oncology	Phase 2
Active Not Recruiting	Study of Abemaciclib in Dedifferentiated Liposarcoma NCT02846987	Memorial Sloan Kettering Cancer Center	Phase 2
Completed	Selinexor in Advanced Liposarcoma NCT02606461	Karyopharm Therapeutics Inc	Phase 2 / Phase 3
Completed	Ph II Cabazitaxel DD Liposarcoma NCT01913652	European Organisation for Research and Treatment of Cancer - EORTC	Phase 2
Withdrawn	Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma NCT00969917	Infinity Pharmaceuticals, Inc.	Phase 2